Damora completes move from Delaware to the Cayman Islands

Damora Therapeutics, Inc. (NASDAQ: DMRA) said it has completed its redomestication from the State of Delaware to the Cayman Islands, effective on July 16, 2026. The company announced the completion in a press release datelined Boston and dated July 17, 2026, which it filed with the Securities and Exchange Commission in a Form 8-K. The company's ordinary shares were set to trade on Nasdaq under a new CUSIP from July 20, 2026.

The terms

Each outstanding share of the Delaware company's common stock converted automatically into one ordinary share of the company, with a par value of $0.00001 per share. Each outstanding share of any series of the Delaware company's preferred stock converted automatically into one outstanding share of the corresponding series of preferred shares of the company. The board of directors approved the redomestication, and stockholders approved it at a Special Meeting of Stockholders held on February 9, 2026.

Each conversion was one for one. The shares will continue to trade on Nasdaq under the symbol "DMRA." The new CUSIP is G2646Y104. The company says the redomestication will not change its business, management, obligations, assets or liabilities.

What the company does

Damora describes itself as an innovative biotechnology company that aims to redefine care for people with hematologic disorders. Its press release says it is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis. The company says it has multiple programs with best-in-class potential that are on track to enter clinical development in 2026, a claim no human data yet support. The release says the company's goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience, with the aim of dramatically improving patient outcomes.

The company's annual report for 2025 describes it as a preclinical stage biotechnology company with a limited operating history. The report says no product candidate has been administered to humans or approved for commercial sale. It says the company is substantially dependent on the success of DMR-001, and that the clinical trials of that candidate may not be successful. The company also relies on collaborations and licensing arrangements with third parties, including Paragon.

The report refers to the company's acquisition of Pre-Acquisition Damora in November 2025. It warns that there is no guarantee the acquisition will increase stockholder value.

Financial position

The annual report shows research and development expense of $26.9 million for 2025, up from $6.4 million for 2024. The company reported a net loss of $209.8 million for 2025, compared with $21.4 million for 2024. Cash used in operations was $6.7 million in 2025 and $18.6 million in 2024. Year-end 2024 cash and cash equivalents were $14.2 million. The annual report still says the company will require substantial additional capital, and that without it the company may have to delay, reduce or eliminate research programs or future commercialization efforts.

What the move does not change

The redomestication is a legal change of home, and the company itself says it alters nothing in the business. The science is untested in people: the annual report says no product candidate has been given to humans, and the release gives no date for any specific program entering the clinic. The net loss of $209.8 million for 2025 compares with cash used in operations of $6.7 million, and the filings in our sources do not break that gap down. The company warns that the clinical trials of DMR-001, on which it is substantially dependent, may not be successful.

Report an error

Companies in this story

DMRADamora Therapeutics, Inc.NASDAQ · United StatesOpen the starter desk